EP3237619A4 - Compositions and methods for inhibiting expression of adamts-5 and adam17 - Google Patents

Compositions and methods for inhibiting expression of adamts-5 and adam17 Download PDF

Info

Publication number
EP3237619A4
EP3237619A4 EP15872041.7A EP15872041A EP3237619A4 EP 3237619 A4 EP3237619 A4 EP 3237619A4 EP 15872041 A EP15872041 A EP 15872041A EP 3237619 A4 EP3237619 A4 EP 3237619A4
Authority
EP
European Patent Office
Prior art keywords
adam17
adamts
compositions
methods
inhibiting expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP15872041.7A
Other languages
German (de)
French (fr)
Other versions
EP3237619A1 (en
EP3237619B8 (en
EP3237619B1 (en
Inventor
Bill Biliang ZHANG
Micky Daniel Tortorella
Zhe Wang
Xiuqun YANG
Qiuyun WANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Argorna Pharmaceuticals Ltd
Guangzhou Ribobio Co Ltd
Original Assignee
GUANGZHOU RIBOBIO CO Ltd
Guangzhou Institute of Biomedicine and Health of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201410828587.5A external-priority patent/CN104560999B/en
Priority claimed from CN201410827650.3A external-priority patent/CN104498498A/en
Application filed by GUANGZHOU RIBOBIO CO Ltd, Guangzhou Institute of Biomedicine and Health of CAS filed Critical GUANGZHOU RIBOBIO CO Ltd
Publication of EP3237619A1 publication Critical patent/EP3237619A1/en
Publication of EP3237619A4 publication Critical patent/EP3237619A4/en
Application granted granted Critical
Publication of EP3237619B1 publication Critical patent/EP3237619B1/en
Publication of EP3237619B8 publication Critical patent/EP3237619B8/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24014—Procollagen N-endopeptidase (3.4.24.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24082—ADAMTS-4 endopeptidase (3.4.24.82), i.e. aggrecanase 1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP15872041.7A 2014-12-25 2015-12-23 Compositions and methods for inhibiting expression of adamts-5 and adam17 Active EP3237619B8 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410828587.5A CN104560999B (en) 2014-12-25 2014-12-25 Suppress siRNA and its application of the genes of ADAMTS 5
CN201410827650.3A CN104498498A (en) 2014-12-25 2014-12-25 siRNA for inhibiting ADAM17 (a disintegrin and metalloprotease 17) genes and application of siRNA
PCT/IB2015/002574 WO2016103042A1 (en) 2014-12-25 2015-12-23 Compositions and methods for inhibiting expression of adamts-5 and adam17

Publications (4)

Publication Number Publication Date
EP3237619A1 EP3237619A1 (en) 2017-11-01
EP3237619A4 true EP3237619A4 (en) 2018-09-12
EP3237619B1 EP3237619B1 (en) 2020-10-21
EP3237619B8 EP3237619B8 (en) 2021-03-10

Family

ID=56149334

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15872041.7A Active EP3237619B8 (en) 2014-12-25 2015-12-23 Compositions and methods for inhibiting expression of adamts-5 and adam17

Country Status (6)

Country Link
US (1) US10709729B2 (en)
EP (1) EP3237619B8 (en)
JP (1) JP6706628B2 (en)
DK (1) DK3237619T3 (en)
ES (1) ES2833028T3 (en)
WO (1) WO2016103042A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3058061A1 (en) * 2016-10-27 2018-05-04 Selexel NEW USE OF DOUBLE STRAND OLIGONUCLEOTIDES
CN111542607A (en) * 2017-11-09 2020-08-14 力博美科股份有限公司 Aptamer aiming at ADAMTS5 and application thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003295600A1 (en) * 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
US20060275794A1 (en) * 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
AU2006251989B2 (en) 2005-05-20 2010-05-27 Alantos-Pharmaceuticals, Inc. Pyrimidine or triazine fused bicyclic metalloprotease inhibitors
ES2413804T3 (en) * 2006-05-19 2013-07-17 Alcon Research, Ltd. RNAi-mediated inhibition of states related to tumor necrosis factor-alpha
US20080311040A1 (en) * 2007-03-06 2008-12-18 Flagship Ventures METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA
AR067786A1 (en) * 2007-08-03 2009-10-21 Alcon Mfg Ltd INHIBITION RELATED TO ARNI (INTERFERENCE RNA) OF TNFALFA SIGNALS (TUMOR NECROSIS FACTOR) FOR THE TREATMENT OF GLAUCOMA
CN102181446B (en) 2011-04-01 2013-01-23 广州市锐博生物科技有限公司 siRNA capability of preventing influenza virus as well as expression vector and pharmaceutical composition of siRNA
CN104560997B (en) 2014-12-25 2018-05-04 中国科学院广州生物医药与健康研究院 Suppress siRNA compositions and its application of ADAMTS-5 and ADAM17 genes
CN104498498A (en) 2014-12-25 2015-04-08 广州市锐博生物科技有限公司 siRNA for inhibiting ADAM17 (a disintegrin and metalloprotease 17) genes and application of siRNA
CN104560999B (en) 2014-12-25 2018-01-09 广州市锐博生物科技有限公司 Suppress siRNA and its application of the genes of ADAMTS 5

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
LOUISE A HURST ET AL: "siRNA knockdown of ADAM-10, but not ADAM-17, significantly reduces fractalkine shedding following pro-inflammatory cytokine treatment in a human adult brain endothelial cell line", NEUROSCIENCE LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 521, no. 1, 17 May 2012 (2012-05-17), pages 52 - 56, XP028495783, ISSN: 0304-3940, [retrieved on 20120526], DOI: 10.1016/J.NEULET.2012.05.057 *
RUO-HUA SONG ET AL: "Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS-4 and ADAMTS-5", ARTHRITIS & RHEUMATISM, vol. 56, no. 2, 1 February 2007 (2007-02-01), US, pages 575 - 585, XP055469796, ISSN: 0004-3591, DOI: 10.1002/art.22334 *
See also references of WO2016103042A1 *
SEKI SHOJI ET AL: "Effect of small interference RNA (siRNA) for ADAMTS5 on intervertebral disc degeneration in the rabbit anular needle-puncture model", ARTHRITIS RESEARCH AND THERAPY, BIOMED CENTRAL, LONDON, GB, vol. 11, no. 6, 4 November 2009 (2009-11-04), pages R166, XP021065267, ISSN: 1478-6354, DOI: 10.1186/AR2851 *
XIANGYU CHU ET AL: "Protective effect of lentivirus-mediated siRNA targeting ADAMTS-5 on cartilage degradation in a rat model of osteoarthritis", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, vol. 31, no. 5, 26 March 2013 (2013-03-26), GR, pages 1222 - 1228, XP055469613, ISSN: 1107-3756, DOI: 10.3892/ijmm.2013.1318 *

Also Published As

Publication number Publication date
DK3237619T3 (en) 2020-11-09
US10709729B2 (en) 2020-07-14
EP3237619A1 (en) 2017-11-01
ES2833028T3 (en) 2021-06-14
JP2018506991A (en) 2018-03-15
JP6706628B2 (en) 2020-06-10
WO2016103042A1 (en) 2016-06-30
EP3237619B8 (en) 2021-03-10
US20180250323A1 (en) 2018-09-06
EP3237619B1 (en) 2020-10-21
WO2016103042A8 (en) 2017-05-11

Similar Documents

Publication Publication Date Title
HRP20181630T1 (en) Methods and compositions for targeted genetic modifications and methods of use
IL273875A (en) Methods and compositions for inhibiting expression of ldha
EP3102576B8 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
EP3233846A4 (en) Inhibitors of bromodomains
HK1232163A1 (en) Compositions and methods for inhibiting gene expression of alpha-1 antitrypsin -1
HUE056172T2 (en) Compositions of selenoorganic compounds and methods of use thereof
EP3201187A4 (en) Compositions and methods for inhibiting bmp
EP3148572A4 (en) Compositions and methods of delivery of deubiquitinase inhibitors
HK1252852A1 (en) Compositions and methods for inhibiting gene expression of hif2alpha
EP3349743A4 (en) Methods and compositions of inhibiting dcn1-ubc12 interaction
EP3122355A4 (en) Compositions and methods for inhibiting bmp
EP3105327A4 (en) Compositions and methods of using microrna inhibitors
EP3190886A4 (en) Compositions and methods of use thereof
EP3177327A4 (en) Inhibitors of myh7b and uses thereof
EP3107902A4 (en) Compounds and methods for inhibiting fascin
EP3110415A4 (en) Compositions and methods for inhibition of mycobacteria
HUE044559T2 (en) Scale inhibitor compositions and methods of using
HK1243404A1 (en) Tryptamide compositions and methods of use
EP3102567A4 (en) Inhibitors of paxillin function and related compositions and methods
EP3237619B8 (en) Compositions and methods for inhibiting expression of adamts-5 and adam17
EP3105332A4 (en) Methods and compositions for inhibiting retinopathy of prematurity
EP3142999A4 (en) Methods and compositions of dasotraline for treatment of adhd
EP3223613A4 (en) 4-fluoro-thio-containing inhibitors of app2, compositions thereof and method of use
AU2014905067A0 (en) Compositions and methods of use
AU2014902829A0 (en) Compositions and Methods of Use

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170717

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/113 20100101AFI20180502BHEP

Ipc: A61K 48/00 20060101ALI20180502BHEP

Ipc: C12N 15/11 20060101ALI20180502BHEP

Ipc: A61P 29/00 20060101ALI20180502BHEP

Ipc: A61P 19/02 20060101ALI20180502BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20180816

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 19/02 20060101ALI20180809BHEP

Ipc: C12N 15/113 20100101AFI20180809BHEP

Ipc: A61P 29/00 20060101ALI20180809BHEP

Ipc: A61K 48/00 20060101ALI20180809BHEP

Ipc: C12N 15/11 20060101ALI20180809BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20190705

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20200429

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GUANGZHOU RIBOBIO CO., LTD.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GUANGZHOU RIBOBIO CO., LTD.

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20201104

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015060944

Country of ref document: DE

Ref country code: FI

Ref legal event code: FGE

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: VALIPAT S.A. C/O BOVARD SA NEUCHATEL, CH

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1325925

Country of ref document: AT

Kind code of ref document: T

Effective date: 20201115

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

GRAT Correction requested after decision to grant or after decision to maintain patent in amended form

Free format text: ORIGINAL CODE: EPIDOSNCDEC

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: CH

Ref legal event code: PK

Free format text: BERICHTIGUNGEN

RIN2 Information on inventor provided after grant (corrected)

Inventor name: YANG, XIUQUN

Inventor name: ZHANG, BILL, BILIANG

REG Reference to a national code

Ref country code: CH

Ref legal event code: PK

Free format text: BERICHTIGUNG B8

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1325925

Country of ref document: AT

Kind code of ref document: T

Effective date: 20201021

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210222

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201021

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210121

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210122

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210121

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201021

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210221

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201021

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201021

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2833028

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20210614

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201021

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602015060944

Country of ref document: DE

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602015060944

Country of ref document: DE

Owner name: GUANGZHOU RIBOBIO CO., LTD., HUANGPU DISTRICT, CN

Free format text: FORMER OWNER: GUANGZHOU RIBOBIO CO., LTD., HUANGPU DISTRICT, GUANGZHOU, CN

Ref country code: DE

Ref legal event code: R081

Ref document number: 602015060944

Country of ref document: DE

Owner name: ARGORNA PHARMACEUTICALS LTD., GUANGZHOU, CN

Free format text: FORMER OWNER: GUANGZHOU RIBOBIO CO., LTD., HUANGPU DISTRICT, GUANGZHOU, CN

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201021

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201021

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201021

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201021

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201021

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201021

RAP4 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: GUANGZHOU RIBOBIO CO., LTD.

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: ARGORNA PHARMACEUTICALS LIMITED

Owner name: GUANGZHOU RIBOBIO CO., LTD.

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201021

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20210819 AND 20210825

26N No opposition filed

Effective date: 20210722

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201223

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201021

REG Reference to a national code

Ref country code: BE

Ref legal event code: PD

Owner name: ARGORNA PHARMACEUTICALS LIMITED; CN

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT; FORMER OWNER NAME: GUANGZHOU RIBOBIO CO., LTD.

Effective date: 20210928

Ref country code: NL

Ref legal event code: PD

Owner name: ARGORNA PHARMACEUTICALS LIMITED; CN

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT; FORMER OWNER NAME: GUANGZHOU RIBOBIO CO., LTD.

Effective date: 20211021

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201021

REG Reference to a national code

Ref country code: FI

Ref legal event code: PCE

Owner name: ARGORNA PHARMACEUTICALS LIMITED

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602015060944

Country of ref document: DE

Owner name: ARGORNA PHARMACEUTICALS LTD., GUANGZHOU, CN

Free format text: FORMER OWNERS: ARGORNA PHARMACEUTICALS LTD., GUANGZHOU, HUANGPU DISTRICT, CN; GUANGZHOU RIBOBIO CO., LTD., HUANGPU DISTRICT, GUANGZHOU, CN

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20220106 AND 20220112

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: ARGORNA PHARMACEUTICALS LIMITED

Effective date: 20220218

REG Reference to a national code

Ref country code: BE

Ref legal event code: PD

Owner name: ARGORNA PHARMACEUTICALS LIMITED; CN

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT; FORMER OWNER NAME: GUANGZHOU RIBOBIO CO., LTD.

Effective date: 20220113

REG Reference to a national code

Ref country code: NL

Ref legal event code: PD

Owner name: ARGORNA PHARMACEUTICALS LIMITED; CN

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT; FORMER OWNER NAME: GUANGZHOU RIBOBIO CO., LTD.

Effective date: 20220314

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210221

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201021

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201021

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201021

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201021

REG Reference to a national code

Ref country code: BE

Ref legal event code: PD

Owner name: ARGORNA PHARMACEUTICALS LIMITED; CN

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT

Effective date: 20220113

REG Reference to a national code

Ref country code: BE

Ref legal event code: PD

Owner name: ARGORNA PHARMACEUTICALS LIMITED; CN

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT; FORMER OWNER NAME: GUANGZHOU RIBOBIO CO., LTD.

Effective date: 20230109

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20221230

Year of fee payment: 8

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230507

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231220

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20231219

Year of fee payment: 9

Ref country code: NL

Payment date: 20231219

Year of fee payment: 9

Ref country code: IE

Payment date: 20231218

Year of fee payment: 9

Ref country code: FR

Payment date: 20231219

Year of fee payment: 9

Ref country code: FI

Payment date: 20231218

Year of fee payment: 9

Ref country code: DK

Payment date: 20231219

Year of fee payment: 9

Ref country code: DE

Payment date: 20231214

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20231218

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240118

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20240110

Year of fee payment: 9